Department of Hematology, Bone Marrow Transplantation Unit, Rigshospitalet University Hospital, Copenhagen, Denmark.
Bone Marrow Transplant. 2012 May;47(5):716-24. doi: 10.1038/bmt.2011.169. Epub 2011 Aug 29.
In this paper we review evidence concerning the impact of hematopoietic SCT (HSCT) on sexuality. The aims are to determine: (1) the sexual changes experienced by patients following allogeneic or autologous HSCT, and its consequences; (2) changes in the sexual function over time and (3) the impact of physiological changes induced by intensive treatment with radiation and chemotherapy on sexual functioning. Four databases were searched for articles published between January 1995 and May 2011. A total of 14 studies were identified and analyzed. We found that (1) multiple aspects of sexuality were affected, and the impact and etiology of these sexual alterations were different between genders, and (2) recovery of sexual activity and pleasure occurred in the first 2 years after HSCT, although it appears that some survivors are more likely to experience sexual dysfunction even 5-10 years after HSCT as compared with controls; and (3) there was contradictory evidence concerning possible differences between allogeneic and autologous HSCT, although there was a significant relation between the sexual dysfunctions and the type of chemotherapy administrated as conditioning and chronic GVHD. Future prospective research in sexual dysfunction with specific reliable validated instruments and more adequate sample sizes will be required to definitively evaluate the impact of HSCT on sexuality.
本文回顾了造血干细胞移植 (HSCT) 对性行为影响的证据。目的是确定:(1) 异基因或自体 HSCT 后患者经历的性变化及其后果;(2) 随时间推移的性功能变化;(3) 放射治疗和化学疗法引起的生理变化对性功能的影响。检索了 1995 年 1 月至 2011 年 5 月期间发表的文章的四个数据库。共确定并分析了 14 项研究。我们发现:(1) 性行为的多个方面受到影响,这些性改变的影响和病因在性别之间不同;(2) HSCT 后 2 年内性活动和性快感恢复,但似乎与对照组相比,即使在 HSCT 后 5-10 年内,一些幸存者更有可能经历性功能障碍;(3) 异基因和自体 HSCT 之间可能存在差异的证据相互矛盾,但接受强化化疗的患者的性障碍与慢性移植物抗宿主病之间存在显著关系。未来需要使用特定的可靠验证工具和更大的样本量进行前瞻性研究,以明确评估 HSCT 对性行为的影响。